Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer
Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase I trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from The University of Texas MD Anderson Cancer Center.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.